Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Organic cation transporters modulate the uptake and cytotoxicity of picoplatin, a third-generation platinum analogue.

More SS, Li S, Yee SW, Chen L, Xu Z, Jablons DM, Giacomini KM.

Mol Cancer Ther. 2010 Apr;9(4):1058-69. doi: 10.1158/1535-7163.MCT-09-1084. Epub 2010 Apr 6.

3.

Organic cation transporters are determinants of oxaliplatin cytotoxicity.

Zhang S, Lovejoy KS, Shima JE, Lagpacan LL, Shu Y, Lapuk A, Chen Y, Komori T, Gray JW, Chen X, Lippard SJ, Giacomini KM.

Cancer Res. 2006 Sep 1;66(17):8847-57.

4.

Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2).

Burger H, Zoumaro-Djayoon A, Boersma AW, Helleman J, Berns EM, Mathijssen RH, Loos WJ, Wiemer EA.

Br J Pharmacol. 2010 Feb;159(4):898-908. doi: 10.1111/j.1476-5381.2009.00569.x. Epub 2010 Jan 8.

5.

Organic cation transporters OCT1, 2, and 3 mediate high-affinity transport of the mutagenic vital dye ethidium in the kidney proximal tubule.

Lee WK, Reichold M, Edemir B, Ciarimboli G, Warth R, Koepsell H, Thévenod F.

Am J Physiol Renal Physiol. 2009 Jun;296(6):F1504-13. doi: 10.1152/ajprenal.90754.2008. Epub 2009 Apr 8.

6.

Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver.

Nies AT, Koepsell H, Winter S, Burk O, Klein K, Kerb R, Zanger UM, Keppler D, Schwab M, Schaeffeler E.

Hepatology. 2009 Oct;50(4):1227-40. doi: 10.1002/hep.23103.

PMID:
19591196
7.

Tissue distribution and ontogeny of organic cation transporters in mice.

Alnouti Y, Petrick JS, Klaassen CD.

Drug Metab Dispos. 2006 Mar;34(3):477-82. Epub 2005 Dec 28.

8.

Genetic variants of organic cation transporter 1 (OCT1) and OCT2 significantly reduce lamivudine uptake.

Choi MK, Song IS.

Biopharm Drug Dispos. 2012 Apr;33(3):170-8. doi: 10.1002/bdd.1783. Epub 2012 Mar 17.

PMID:
22415520
9.

Functional characterization of the organic cation transporters (OCTs) in human airway pulmonary epithelial cells.

Ingoglia F, Visigalli R, Rotoli BM, Barilli A, Riccardi B, Puccini P, Dall'Asta V.

Biochim Biophys Acta. 2015 Jul;1848(7):1563-72. doi: 10.1016/j.bbamem.2015.04.001. Epub 2015 Apr 13.

PMID:
25883089
10.
11.

Genetic variants of organic cation transporter 2 (OCT2) significantly reduce metformin uptake in oocytes.

Song IS, Shin HJ, Shin JG.

Xenobiotica. 2008 Sep;38(9):1252-62. doi: 10.1080/00498250802130039 .

PMID:
18728938
12.

Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics.

Higgins JW, Bedwell DW, Zamek-Gliszczynski MJ.

Drug Metab Dispos. 2012 Jun;40(6):1170-7. doi: 10.1124/dmd.112.044875. Epub 2012 Mar 9.

13.

Evaluation of the transporter-mediated herb-drug interaction potential of DA-9801, a standardized dioscorea extract for diabetic neuropathy, in human in vitro and rat in vivo.

Song IS, Kong TY, Jeong HU, Kim EN, Kwon SS, Kang HE, Choi SZ, Son M, Lee HS.

BMC Complement Altern Med. 2014 Jul 17;14:251. doi: 10.1186/1472-6882-14-251.

14.

Functional mapping of rbOCT1 and rbOCT2 activity in the S2 segment of rabbit proximal tubule.

Kaewmokul S, Chatsudthipong V, Evans KK, Dantzler WH, Wright SH.

Am J Physiol Renal Physiol. 2003 Dec;285(6):F1149-59. Epub 2003 Aug 26.

15.

Oxaliplatin transport mediated by organic cation/carnitine transporters OCTN1 and OCTN2 in overexpressing human embryonic kidney 293 cells and rat dorsal root ganglion neurons.

Jong NN, Nakanishi T, Liu JJ, Tamai I, McKeage MJ.

J Pharmacol Exp Ther. 2011 Aug;338(2):537-47. doi: 10.1124/jpet.111.181297. Epub 2011 May 23.

16.

Proton pump inhibitors inhibit metformin uptake by organic cation transporters (OCTs).

Nies AT, Hofmann U, Resch C, Schaeffeler E, Rius M, Schwab M.

PLoS One. 2011;6(7):e22163. doi: 10.1371/journal.pone.0022163. Epub 2011 Jul 14.

17.

Selective regulation of cardiac organic cation transporter novel type 2 (OCTN2) in dilated cardiomyopathy.

Grube M, Ameling S, Noutsias M, Köck K, Triebel I, Bonitz K, Meissner K, Jedlitschky G, Herda LR, Reinthaler M, Rohde M, Hoffmann W, Kühl U, Schultheiss HP, Völker U, Felix SB, Klingel K, Kandolf R, Kroemer HK.

Am J Pathol. 2011 Jun;178(6):2547-59. doi: 10.1016/j.ajpath.2011.02.020.

18.

Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteins.

Minematsu T, Giacomini KM.

Mol Cancer Ther. 2011 Mar;10(3):531-9. doi: 10.1158/1535-7163.MCT-10-0731. Epub 2011 Jan 20.

19.

Influence of Oct1/Oct2-deficiency on cisplatin-induced changes in urinary N-acetyl-beta-D-glucosaminidase.

Franke RM, Kosloske AM, Lancaster CS, Filipski KK, Hu C, Zolk O, Mathijssen RH, Sparreboom A.

Clin Cancer Res. 2010 Aug 15;16(16):4198-206. doi: 10.1158/1078-0432.CCR-10-0949. Epub 2010 Jul 2.

20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk